A Phase I, Randomized, Double-Blind, Adaptive, Placebo-Controlled, Single- Ascending Dose and Multiple-Ascending Dose, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of RO7763505 Following Oral Administration in Healthy Participants and Patients With Stable Coronary Artery Disease
Latest Information Update: 13 May 2026
At a glance
- Drugs RO 7763505 (Primary)
- Indications Coronary artery disease
- Focus Adverse reactions; First in man
- Sponsors Roche
Most Recent Events
- 20 Apr 2026 Completion date changed from 31 Dec 2027 to 15 Feb 2028.
- 26 Mar 2026 New trial record